<DOC>
	<DOCNO>NCT01823081</DOCNO>
	<brief_summary>Eligible eye randomize two group . Group A receive three intravitreal injection bevacizumab 4 week interval . In group B , three intravitreal injection combine bevacizumab fasudil perform frequency . Best correct visual acuity ( BCVA ) central macular thickness ( CMT ) evaluate prior injection every 4 week 6 month . Fluorescein angiography perform baseline week 12 24 . The two group compare term BCVA CMT change .</brief_summary>
	<brief_title>Combined Intravitreal Fasudil Bevacizumab Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fasudil</mesh_term>
	<mesh_term>1- ( 5-Isoquinolinesulfonyl ) -2-Methylpiperazine</mesh_term>
	<criteria>Diabetic patient diabetic macular edema ( DME ) : Central macula thickness &gt; 250Î¼m Visual acuity &lt; 20/40 No active proliferative diabetic retinopathy No history intravitreal antiVEGF drug injection macular laser photocoagulation ( MPC ) within past 3 month History vitrectomy History cataract surgery within past 6 month History glaucoma uveitis Presence macular disorder DME Presence traction macula Significant medium opacity Serum creatinine &gt; 3mg/ml</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>